Đánh giá kết quả hóa xạ trị đồng thời ở bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn III tại bệnh viện K

Aim: To assess the effectiveness and some toxicities of concurrent chemoradiotherapy for the treatment of stage IIIA (N2) and IIIB non-small cell lung cancer patients. Patients and Methods: 50 patients with stage IIIA (N2) and IIIB NSCLC who had ECOG 0-1 underwent 4 cycles of EP concurrently with radiation .60Gy. End points included response rate, survival and advert events. Results: The overall response rate was 66 percent and complete response rate was 14 percent. The mean survival time was 15 months. There were some side effects including neutropenia (96 percent), esophagitis (54 percent) and local skin reaction (100 percent), but almost ofthem were mild or moderate and recover in a short time. Conclussions: Concurrent chemoradiotherapy for patients with locally advanced NSCLC has high rate of response and acceptable toxicities.